Guggenheim raises First Tracks stock price target to $110 on celiac data

Guggenheim raised its First Tracks Biotherapeutics price target to $110 from $100 and reiterated Buy after Phase Ib results for ANB033 showed statistically significant protection against gluten-induced intestinal damage in 32 celiac disease patients (treatment difference +0.49 in Vh:Cd; p=0.009). The company expects Cohort 2 topline data in Q1 2027 and plans additional programs in 2027; Guggenheim increased its probability-of-success assumptions by 5% across programs while accounting for recent dilution. The stock has returned 144% year to date and is near its $49.91 52-week high, although InvestingPro flags potential overvaluation.

Analysis

The key issue is not the direction of one analyst’s target revision, but whether a small early-stage study can support a multi-indication valuation before the next meaningful readouts. With the shares near their recent high after a substantial run, positive headlines may have pulled forward some of the near-term upside; widely differing analyst targets underscore how assumption-sensitive the valuation remains, not how much downside is protected.

For the next few months, the full dataset is the main quality check: inspect effect consistency, safety, and whether the reported benefit is robust enough to justify advancement. Cohort 2 data and further program milestones are much farther out, leaving a long period in which sentiment, financing expectations, or trial execution can dominate. The capital raise may reduce near-term funding pressure, but does not remove the risk of future dilution if development broadens or timelines slip.

The contrarian risk is treating a statistically positive Phase Ib result as proof of commercial differentiation across several autoimmune indications. Conversely, a durable, reproducible effect could support a broader platform valuation. That thesis is falsified by weaker follow-up data, tolerability concerns, delayed milestones, or guidance indicating materially greater funding needs.

Key Decisions for Investors

• Do not chase the headline-driven move. For new exposure, wait for the full dataset and assess consistency and safety before adding; near-term upside is difficult to underwrite against the long wait for later-stage evidence.
• For existing holders, consider reducing position size or taking partial gains after the sharp rerating rather than treating analyst targets as downside support. Reassess after the conference dataset and on any material change in clinical timelines or funding outlook.
• Watch Cohort 2 topline data and the eosinophilic esophagitis readout as separate, later catalysts; do not assume success in celiac disease transfers across indications. Track enrollment pace, safety disclosures, and cash runway for signs of delay or additional dilution risk.
• A constructive thesis requires a robust full dataset and on-time execution. Weaken or exit that thesis if follow-up does not support the initial signal, safety changes the benefit-risk profile, or management delays programs or signals substantially higher funding needs.